E
Eiji Shimizu
Researcher at Tottori University
Publications - 3
Citations - 4086
Eiji Shimizu is an academic researcher from Tottori University. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 3, co-authored 3 publications receiving 3780 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
Journal ArticleDOI
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
Kenji Tamura,Isamu Okamoto,Tatsuhiko Kashii,S. Negoro,T. Hirashima,S. Kudoh,Yukito Ichinose,N Ebi,K Shibata,Toshihide Nishimura,Nobuyuki Katakami,T Sawa,Eiji Shimizu,Junya Fukuoka,Taroh Satoh,Masahiro Fukuoka +15 more
TL;DR: Gefitinib chemotherapy in patients with advanced NSCLC harbouring EGFR mutations was highly effective, demonstrating the benefit to patients of selecting gefit inib treatment based on their EGFR mutation status.
Journal ArticleDOI
Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +19 more
TL;DR: Overall survival was re-evaluated using updated data and multivariate analysis using Cox proportional hazards model revealed that none of covariates (treatment arm, smoking status, sex, age, postoperative recurrence or IIIB/IV, and mutation type) significantly affected OS.